Lassa fever remains endemic in parts of West Africa and continues to pose as a quiescent threat globally. We described the background on Lassa fever, factors contributing to its emergence and spread, preventive measures, and potential solutions. This review provides a holistic and comprehensive source for academicians, clinicians, researchers, policymakers, infectious disease epidemiologists, virologists, and other stakeholders.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866331 | PMC |
| http://dx.doi.org/10.4269/ajtmh.20-0487 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Knowledge, attitude and practice of Lassa fever prevention among adults in Bali Local Government Area, Taraba State, Nigeria.
J Prev Med Hyg
September 2024
College of Medicine Imo State University, Owerri, Imo State, Nigeria.
Introduction: Lassa fever (LF), a public health problem of great importance endemic in West Africa, is an acute and sometimes fatal viral haemorrhagic disease which leads to mortality. The current study assessed the knowledge, attitude and practice of Lassa fever prevention among adults in Bali Local Government Area, Taraba State, Nigeria.
Methods: Descriptive study design and Cross sectional study design was used for this study.
Current perspectives on vaccines and therapeutics for Lassa Fever.
Virol J
December 2024
Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.
Lassa virus, the cause of deadly Lassa fever, is endemic in West Africa, where thousands of cases occur on an annual basis. Nigeria continues to report increasingly severe outbreaks of Lassa Fever each year and there are currently no approved vaccines or therapeutics for the prevention or treatment of Lassa Fever. Given the high burden of disease coupled with the potential for further escalation due to climate change the WHO has listed Lassa virus as a priority pathogen with the potential to cause widespread outbreaks.
View Article and Find Full Text PDFDescriptive epidemiology of Lassa fever, its trend, seasonality, and mortality predictors in Ebonyi State, South- East, Nigeria, 2018-2022.
BMC Public Health
December 2024
Department of Epidemiology and Medical Statistics, Faculty of Public Health, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Background: Nigeria is an epicenter for Lassa fever. Ebonyi state is located in the South-Eastern region of Nigeria where a high burden of Lassa fever has been reported. Therefore, this study was designed to assess the epidemiology of Lassa fever, its seasonality, trend, and mortality predictors in Ebonyi state, South-East, Nigeria.
View Article and Find Full Text PDFSystematic Review and Meta-Analysis of Female Reproductive Health Following Ebola Virus Disease.
Am J Trop Med Hyg
December 2024
Department of Medicine, Section of Infectious Diseases, School of Medicine, Tulane University, New Orleans, Louisiana.
Article Synopsis
- The systematic review focuses on reproductive health issues faced by female survivors of Lassa fever and Ebola virus disease.
- Thirteen studies reviewed predominantly highlight negative outcomes related to reproductive health among EVD survivors, including menstrual irregularities and pregnancy loss, with no research identified on LF survivors.
- The analysis indicates that about 14% of female EVD survivors experience adverse reproductive health outcomes, revealing a significant need for further research in this area.
U-73122, a phospholipase C inhibitor, impairs lymphocytic choriomeningitis virus virion infectivity.
J Gen Virol
December 2024
Laboratory of Emerging Viral Diseases, International Research Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Lassa virus (LASV) is an Old World (OW) mammarenavirus that causes Lassa fever, a life-threatening acute febrile disease endemic in West Africa. Lymphocytic choriomeningitis virus (LCMV) is a worldwide-distributed, prototypic OW mammarenavirus of clinical significance that has been largely neglected as a human pathogen. No licensed OW mammarenavirus vaccines are available, and the current therapeutic option is limited to the off-label use of ribavirin, which offers only partial efficacy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!